India, April 11 -- Verve Therapeutics, Inc. (VERV), Friday announced that the company's investigational base editing medicine VERVE-102 has received the U.S. Food and Drug Administration's Fast Track designation for the treatment of patient groups with hyperlipidemia and high lifetime cardiovascular risk to reduce low-density lipoprotein cholesterol.
Currently, VERVE-102 is being tested in the Phase 1b Heart-2 clinical trial, evaluating the safety and tolerability of VERVE-102 administration in adult patients with heterozygous familial hypercholesterolemia and/or premature coronary artery disease who require additional lowering of LDL-C.
The company expects to announce the demographic and initial safety and efficacy data from the Heart-2 ...